Home / Europe / Slovakia / Life Sciences & Healthcare

Life Sciences & Healthcare

We work with and have established long-term relationships with the top 100 life sciences companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies. Our life sciences teams in Central and Eastern Europe advise leading global business groups in the sector on transactions, commercial agreements, compliance, investigations and litigation, very often across multiple jurisdictions in the region and beyond.

We can help you to navigate the regulatory landscape and to ensure compliance with both local laws and global policies.

With over 480 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your life sciences business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the life sciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice.

Our Slovak office works intensively with companies from the life sciences sector. Our team in Bratislava provides comprehensive advice on regulatory issues and compliance with statutory provisions, as well as on issues specific to the sector, such as the labelling and advertising of pharmaceutical and cosmetic products and the registration of drugs and medicines. Furthermore, our experts will provide you with support in obtaining permissions to trade in medicines and advice on the various aspects of clinical testing.


Feed

05/12/2022
EU Com­mis­sion pro­poses to mod­ern­ise product li­ab­il­ity rules for green and...
Cur­rent product li­ab­il­ity rules, based on the 85/374/EGK Product Li­ab­il­ity Dir­ect­ive (PLD), are nearly 40 years old and no longer suit­able for the mod­ern di­git­al age. Among oth­er things, the PLD is un­cer­tain...
22/11/2022
Glob­al Life Sci­ences & Health­care For­um 2022: Life Sci­ences are reap­ing...
Di­git­al trans­form­a­tion in life sci­ences is cre­at­ing op­por­tun­it­ies to counter health­care’s most in­tract­able prob­lems from treat­ing rare dis­eases to ac­cel­er­at­ing dia­gnostics and re­du­cing treat­ment back­logs...
09/11/2022
Glob­al Life Sci­ences & Health­care For­um 2022: The Life Sci­ences sec­tor...
The open­ing of COP27 has brought an in­tense glob­al fo­cus on cli­mate change and the tower­ing de­mands needed to reach car­bon net zero and to pro­tect the en­vir­on­ment. United Na­tions Gen­er­al Sec­ret­ary Ant­o­nio...
02/11/2022
Glob­al Life Sci­ences & Health­care For­um 2022: The leg­al sec­tor has a key...
The United Na­tions has pledged to use its pur­chas­ing fire­power to ac­cel­er­ate sus­tain­ab­il­ity along the health­care sup­ply chan­nel and called on the leg­al sec­tor to sup­port its ef­forts. Law­yers are crit­ic­al...
20/09/2022
Skin­teg­rated Cos­me­ceut­ic­als - is Pharma be­com­ing sexy (again?)
Case Study: Skin­tegra, Skin­teg­rity Cos­me­ceut­ic­als are sexy right now.  They’re less reg­u­lated than the phar­ma­ceut­ic­al in­dustry (al­though don’t let that fool you in­to be­liev­ing you can say whatever...
15/09/2022
Phar­ma­ceut­ic­al ad­vert­ising reg­u­la­tion and med­ic­al device ad­vert­ising in...
1. Which laws are ap­plic­able re­gard­ing ad­vert­ising of medi­cines and med­ic­al devices? The primary leg­al source is Act No. 147/2001 Coll. on Ad­vert­ise­ment, as amended (“Act on Ad­vert­ise­ment”);Act No...
13/09/2022
UPC Rules of Pro­ced­ure go in­to force with judg­ments to be made pub­lic
The entry in­to force of the Rules of Pro­ced­ure is part of the fi­nal pre­par­a­tions for the United Pat­ent Court (UPC), which is cur­rently ex­pec­ted to start work in early 2023. After the bod­ies of the UPC...
08/09/2022
Can­nabis law and le­gis­la­tion in Slov­akia
Med­ic­al use It is not per­mit­ted to grow, im­port or sell can­nabis for med­ic­al use in Slov­akia. However, it is now per­mit­ted to grow can­nabis for the re­search pur­poses, sub­ject to ap­prov­al gran­ted by the...
30/08/2022
Phar­ma­ceut­ic­al trade marks - a real pain in the bum?
An EU IPO Case Study: Proc­to­LYSY­AL v PRO­COTOL­IZ­IN Sum­mary I al­ways like to start at the end.  No nasty sur­prises and you know what to ex­pect.  In this case study, the trade marks ‘proc­to­LYSY­AL’...
02/08/2022
Leg­al is­sues in the meta­verse / Part 4 - Ex­pec­ted im­pact of the EU Ar­ti­fi­cial...
Part 4 - Ex­pec­ted im­pact of the EU Ar­ti­fi­cial In­tel­li­gence Reg­u­la­tion, the meta­verse as a work­place In our first art­icle, we ex­amined the nature of the meta­verse, the shared vir­tu­al world. The emer­gence...
27/07/2022
Leg­al is­sues in the meta­verse / Part 3 - Data pro­tec­tion chal­lenges, the...
Part 3 - Data pro­tec­tion chal­lenges, the im­port­ance of cy­ber­se­cur­ity, ad­vert­ising reg­u­la­tion in the meta­verse In our first art­icle, we ex­amined the nature of the meta­verse, the shared vir­tu­al world...
26/07/2022
European Bolar Pro­vi­sions in Slov­akia
1. How is Bolar im­ple­men­ted? Bolar ex­emp­tion is im­ple­men­ted in Art­icle 49 of Act No. 362/2011 Coll. on Medi­cines and Med­ic­al Devices and on Amend­ments to Cer­tain Acts as amended (here­in­after as “Act”)...
Comparable